<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Syphilis in pregnancy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Syphilis in pregnancy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Syphilis in pregnancy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Errol R Norwitz, MD, PhD, MBA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles B Hicks, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeanne Marrazzo, MD, MPH, FACP, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Syphilis is a systemic infection caused by the spirochete
         <em>
          Treponema pallidum
         </em>
         . Infection is of particular concern during pregnancy because of the risk of transplacental transmission to the fetus. Congenital infection can be associated with several adverse outcomes, including perinatal death.
        </p>
        <p>
         Issues related to syphilis during pregnancy will be reviewed here. Syphilis in children and nonpregnant adults are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">
          "Congenital syphilis: Management and outcome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PREVALENCE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          United States
         </strong>
         – The rate of primary and secondary syphilis among females in the United States has been increasing almost every year and in all age groups since historic lows in 2000 and 2001 [
         <a href="#rid1">
          1
         </a>
         ]. In females of reproductive age, the rate increased by 676 percent from 2012 to 2021 (from 2.1 to 16.3 per 100,000 population).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After a steady decline, the rate of congenital syphilis has also been increasing during this period, corresponding to the increasing incidence of syphilis in reproductive-aged females. In 2022, 3761 cases of congenital syphilis were reported, including 231 (6 percent) stillbirths and 3530 (94 percent) live births (with 51 subsequent infant deaths) [
         <a href="#rid2">
          2
         </a>
         ]. This represents a more than fourfold increase in congenital syphilis since 2017 (941 congenital cases [
         <a href="#rid3">
          3
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Globally
         </strong>
         – Globally, the estimated prevalence of maternal syphilis in 2016 was 0.69 percent (95% CI 0.57-0.81), resulting in a global congenital syphilis rate of 473 (95% CI 385-561) per 100,000 live births [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1239743989">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Syphilis occurs with equal frequency in males and females worldwide [
         <a href="#rid5">
          5
         </a>
         ], but males are more commonly infected in the United States. However, the male-to-female rate ratio in the United States is declining because, although infection rates in both males and females are increasing, the infection rate in females is increasing faster than that in males [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Syphilis is more common among pregnant people from vulnerable populations. Specific risk factors include [
         <a href="#rid7">
          7,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residence in a community with high syphilis rates (the Centers for Disease Control and Prevention [CDC] has not defined the threshold for a high rate but 4.6 per 100,000 population is a reasonable threshold [
         <a href="#rid2">
          2
         </a>
         ])
         <strong>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Misusing drugs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having a sexually transmitted infection (STI) during pregnancy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having more than one or a new sex partner
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having a sex partner with an STI
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having sex in conjunction with drug use or transactional sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Entering prenatal care during the second trimester or later or no prenatal care
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Being incarcerated or having a partner who is incarcerated
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having unstable housing or homelessness
        </p>
        <p>
        </p>
        <p>
         However, in one study, approximately 50 percent of pregnant people with syphilis in the United States had none of 16 traditional risk factors for the disease [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The epidemiology of congenital syphilis is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          MATERNAL ACQUISITION OF INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sexual transmission requires exposure to open lesions in which microorganisms are present. The spirochetes pass from the lesion across intact non-keratinized epithelium or abraded skin into the new host. The efficiency of sexual (horizontal) transmission is estimated to be approximately 30 percent [
         <a href="#rid9">
          9
         </a>
         ]. The incubation period varies from 10 to 90 days (average approximately three weeks); larger inocula shorten this incubation period [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Transmission'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H836346994">
         <span class="h1">
          MATERNAL CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of syphilis are not affected by the pregnant state. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          MATERNAL SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Universal antepartum screening is widely recommended because screening followed by treatment with appropriate antibiotics usually prevents adverse maternal and offspring outcomes  (
         <a class="graphic graphic_algorithm graphicRef116084" href="/z/d/graphic/116084.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid11">
          11-13
         </a>
         ]. Screening is performed using a serologic test; either a treponemal or nontreponemal test can be used. All of the tests have similar sensitivity and specificity, so preference is based on other factors (eg, cost, time, personnel requirements). (See
         <a class="local">
          'Serologic testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3398067697">
         <span class="h2">
          Candidates and timing of initial and repeat screening
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All pregnant people: screen at the first prenatal encounter
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant people at high risk of infection: repeat screening at 28 to 32 weeks
         <strong>
          and
         </strong>
         at delivery
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant people who have not been screened in pregnancy or who give birth to a stillborn after 20 weeks of gestation: screen at delivery
        </p>
        <p>
        </p>
        <p>
         The United States CDC and many other global and national organizations recommend screening all pregnant people for syphilis at the first prenatal visit [
         <a href="#rid14">
          14-19
         </a>
         ]. The cost and morbidity associated with screening for syphilis are low and the benefit of detecting and treating the disease is high for both mother and child. Universal screening for syphilis has the advantage of removing the stigma of testing since all pregnant people are screened, not just those considered to be at higher risk. The major harm of screening is the anxiety associated with a false-positive result [
         <a href="#rid20">
          20,21
         </a>
         ]. (See
         <a class="local">
          'False-positive serologic tests in pregnancy'
         </a>
         below.)
        </p>
        <p>
         For pregnant people who are at high risk for acquiring syphilis (see
         <a class="local">
          'Epidemiology'
         </a>
         above), the CDC recommends repeating screening during the third trimester at 28 to 32 weeks and again at delivery [
         <a href="#rid22">
          22
         </a>
         ]. Local prevalence rates are available from the CDC, which annually publishes
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Fsyphilis%2Fstats.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLEJ12R6Za36pTwkTxp4u5aP7HFPlysL0RPJ2GoWkbXx7rwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=4794" target="_blank">
          prevalence rates in the United States
         </a>
         based on variables such as county, sex, age group, ethnicity, and sexual behavior, but not pregnancy status. Routinely rescreening all pregnant people in the third trimester and/or at delivery was cost-effective in some modeling studies but not in others [
         <a href="#rid23">
          23-25
         </a>
         ]
        </p>
        <p class="headingAnchor" id="H3479864598">
         <span class="h2">
          Opportunities for screening outside of traditional prenatal care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any encounter between a pregnant person and a medical or public health professional is an opportunity to identify and treat syphilis. Screening for syphilis should be considered when a pregnancy is diagnosed in a nonobstetric setting, such as a drug treatment center, prison, syringe services program, emergency medicine department, or outreach program, given that pregnant people with syphilis are less likely to receive prenatal care.
        </p>
        <p>
         Rapid point of care tests are less accurate than standard nontreponemal and treponemal tests [
         <a href="#rid26">
          26
         </a>
         ], but can be helpful in guiding initial treatment decisions in patients in whom return for follow-up is uncertain and thus reduce the risk of adverse outcomes from congenital syphilis [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Rapid serologic tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3096498929">
         <span class="h2">
          Concurrent HIV screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         All pregnant people should be offered HIV counseling and testing using an opt-out approach [
         <a href="#rid28">
          28
         </a>
         ]. HIV testing is strongly recommended for those known to have a sexually transmitted disease, such as syphilis, due to the high risk of coexistent disease. HIV testing should be repeated at the time of repeat syphilis screening. (See
         <a class="medical medical_review" href="/z/d/html/446.html" rel="external">
          "Prenatal care: Initial assessment", section on 'HIV'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H442895689">
         <span class="h2">
          Serologic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients, the diagnosis of syphilis is made through serologic testing of blood specimens. Methods that detect the organism directly (eg, darkfield microscopy) are not generally available.
        </p>
        <p>
         Serologic testing to diagnose syphilis should include the use of both treponemal and nontreponemal tests:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specific treponemal tests include fluorescent treponemal antibody absorption (FTA-ABS), microhemagglutination test for antibodies to
         <em>
          T. pallidum
         </em>
         (MHA-TP),
         <em>
          T. pallidum
         </em>
         particle agglutination assay (TPPA),
         <em>
          T. pallidum
         </em>
         enzyme immunoassay (TP-EIA), and chemiluminescence immunoassay (CIA). The TP-EIA is a commonly performed treponemal test because it allows inexpensive volume testing of blood samples with minimal time requirements for laboratory personnel.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nontreponemal tests include Rapid Plasma Reagin (RPR), Venereal Disease Research Laboratory (VDRL), and Toluidine Red Unheated Serum Test (TRUST). The RPR and VDRL are the most commonly performed nontreponemal tests.
        </p>
        <p>
        </p>
        <p>
         Either test can be used as the initial screening test, depending on the preference of the laboratory performing the test  (
         <a class="graphic graphic_algorithm graphicRef116084" href="/z/d/graphic/116084.html" rel="external">
          algorithm 1
         </a>
         ). Most laboratories use a testing strategy that screens with a treponemal assay (most often an enzyme immunoassay) and then use a nontreponemal test (RPR or VDRL) for confirmatory testing. Confirmatory testing is necessary due to the potential for a false-positive screening test result. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Serologic testing algorithms'
         </a>
         .)
        </p>
        <p>
         The diagnostic interpretation of syphilis serology, including interpretation of testing in patients with prior syphilis, is the same as in nonpregnant individuals. As an example, in a patient without prior syphilis, a diagnosis of syphilis is made when both treponemal tests and nontreponemal tests are reactive. A more detailed discussion of how to interpret serologic testing is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Interpretation of serologic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1830478077">
         <span class="h2">
          False-positive serologic tests in pregnancy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – Biologic false-positive nontreponemal and treponemal results are relatively common among pregnant people with an initial positive screening test. In a study of 75,056 pregnancies, 221 patients (0.29 percent) had an initial positive screening test and 183 of these patients (83 percent) were subsequently found to have a false-positive test (false-positive rate: 244 cases per 100,000 pregnancies) [
         <a href="#rid29">
          29
         </a>
         ]. False-positive rates did not differ between traditional algorithms starting with a nontreponemal test and reverse algorithms starting with a treponemal test.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient evaluation during pregnancy
         </strong>
         – Given the high risk that an initial positive test is a false-positive, testing algorithms should include confirmatory testing  (
         <a class="graphic graphic_algorithm graphicRef116084" href="/z/d/graphic/116084.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid30">
          30
         </a>
         ]. When an initial treponemal screening test is positive but the follow-up nontreponemal result is negative, treponemal reflexive testing is performed. If reflex testing is also positive, the negative nontreponemal test may be secondary to a prozone effect. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Prozone reaction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A positive (reactive) low titer nontreponemal screening test can be considered a transient biologic false-positive result due to pregnancy if the follow-up treponemal test is negative and the patient is asymptomatic and at low risk of acute syphilis. False-positive nontreponemal test results can also be related to an acute event, such as an acute febrile illness or recent immunization (including a COVID-19 vaccine [
         <a href="#rid31">
          31
         </a>
         ]). Test abnormalities attributed to these conditions are usually transitory, typically lasting for six months or less. In addition to pregnancy, conditions associated with a false-positive CIA treponemal test include advanced age (&gt;50 years), tumor, dialysis, autoimmune disease, and systemic infections unrelated to syphilis (eg, tuberculosis, rickettsial diseases, endocarditis) [
         <a href="#rid32">
          32
         </a>
         ], while a false-positive EIA has been associated with advanced age (≥40 years) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up after delivery
         </strong>
         – All patients with biologic false-positives attributed to pregnancy or another transient event should undergo follow-up testing at least four to six weeks after giving birth. If the discordancy persists, then the need for further evaluation can be determined on a case-by-case basis, taking into account factors such as symptoms (eg, signs/symptoms of autoimmune disease) and risk of syphilis infection [
         <a href="#rid30">
          30,32-36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Positive nontreponemal/negative treponemal'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1968244829">
         <span class="h1">
          STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The stage of syphilis is clinically important because it impacts the treatment regimen and the risk of vertical transmission (see
         <a class="local">
          'Vertical transmission (congenital syphilis)'
         </a>
         below). Patients whose screening test for syphilis is positive should be staged based on history and physical examination. Each stage of syphilis has characteristic clinical findings that are not altered by pregnancy. A synopsis is provided below and in the table  (
         <a class="graphic graphic_table graphicRef79946" href="/z/d/graphic/79946.html" rel="external">
          table 1
         </a>
         ). A detailed discussion of staging, including photographs of lesions, can be found separately. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Stages of disease'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary syphilis
         </strong>
         — When symptomatic, the first manifestation of syphilis is a skin lesion that may be macular initially but typically evolves into a painless papule at the site of inoculation. This soon ulcerates to produce the classic chancre(s) of primary syphilis, a 1 to 2 centimeter painless ulcer with a raised, indurated margin that may be genital or extragenital. The ulcer is associated with mild to moderate regional lymphadenopathy that may be bilateral. Chancres heal spontaneously within three to six weeks, even in the absence of treatment. The primary stage of syphilis may not be noticed if the lesion is on the vaginal or cervical epithelium. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Primary syphilis (chancre)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary syphilis
         </strong>
         — Secondary syphilis is a disseminated systemic process that occurs in approximately 25 percent of untreated patients, usually beginning six weeks to six months after the appearance of the chancre of primary syphilis. A generalized maculopapular skin rash involving the palms and soles and mucous membranes is characteristic of this stage of the infection. Generalized lymphadenopathy may accompany the rash. Additional clinical features may include fever, pharyngitis, weight loss, and condylomata lata. Although spirochetes can be found in the cerebrospinal fluid (CSF) of around 40 to 50 percent of patients with early syphilis [
         <a href="#rid37">
          37
         </a>
         ], neurologic manifestations are uncommon. The rash of secondary syphilis typically resolves spontaneously within two to six weeks. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Secondary syphilis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Latent syphilis
         </strong>
         — In the United States, latent syphilis is defined as "early latent" when it is possible to document a nonreactive syphilis serology within the past year or a history of symptoms of early syphilis within the past year. Otherwise, the disease is considered "late latent". Latent syphilis is by definition asymptomatic. If untreated, a small proportion of patients will develop signs and symptoms of secondary or late syphilis, but many will remain asymptomatic. People with latent syphilis can transmit the infection to sexual partners, or the fetus; however, this is considerably less common in late latent syphilis. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Latent syphilis (asymptomatic)'
         </a>
         and
         <a class="local">
          'Vertical transmission (congenital syphilis)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tertiary (late) syphilis
         </strong>
         — Tertiary syphilis is infrequently diagnosed and is characterized by slowly progressive signs and symptoms. Clinical manifestations include gumma formation and cardiovascular disease. Such manifestations usually develop 5 to 20 years after the disease has become latent. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Late syphilis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurosyphilis
         </strong>
         — Early in the course of syphilis infection,
         <em>
          T. pallidum
         </em>
         can enter the central nervous system and subsequently produce a variety of signs and symptoms during both early and late syphilis. Neurosyphilis is described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H909586315">
         <span class="h1">
          MATERNAL TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H304199471">
         <span class="h2">
          Treatment setting
         </span>
         <span class="headingEndMark">
          —
         </span>
         The authors administer treatment for syphilis in an outpatient setting, and counsel patients about potential side effects and when to contact their provider. Others may choose to administer the first dose of penicillin in a labor and delivery unit with continuous fetal monitoring for at least 24 hours in pregnancies that have reached a gestational age when intervention would be considered in case of Jarisch-Herxheimer reaction and its potential sequelae (eg, preterm labor, nonreassuring fetal heart rate pattern) [
         <a href="#rid7">
          7
         </a>
         ]. There is no consensus regarding the best approach; both are acceptable. (See
         <a class="local">
          'Potential complications of treatment: Jarisch-Herxheimer reaction'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1972014971">
         <span class="h2">
          Preferred regimen: penicillin
         </span>
        </p>
        <p class="headingAnchor" id="H4232330360">
         <span class="h3">
          Key principles
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Penicillin G benzathine
         </strong>
         <strong>
          is the standard for the treatment
         </strong>
         of syphilis in both pregnant and nonpregnant individuals. No clinically relevant penicillin-resistant strains of
         <em>
          T. pallidum
         </em>
         have been identified to date.
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          Penicillin G benzathine
         </a>
         therapy is effective for treating maternal disease, preventing transmission to the fetus, and treating established fetal disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnant people with penicillin allergy should be desensitized
         </strong>
         <strong>
          and treated with
         </strong>
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         <strong>
         </strong>
         because penicillin G benzathine is considered the only appropriate treatment of syphilis during pregnancy. Desensitization may be performed in the outpatient or inpatient setting, depending on the severity of the past reaction and available resources. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions", section on 'Risk stratification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions", section on 'Setting and staffing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The appropriate
         </strong>
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         <strong>
          regimen depends on the stage of disease
         </strong>
         (
         <a class="graphic graphic_table graphicRef79645" href="/z/d/graphic/79645.html" rel="external">
          table 2
         </a>
         ). The pregnant state does not affect the maternal response to treatment. (See
         <a class="local">
          'Patients with immediate type allergic reactions to penicillin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bicillin L-A must be distinguished from Bicillin C-R
         </strong>
         –
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          Penicillin G benzathine
         </a>
         (long-acting intramuscular) is marketed under the trade name Bicillin L-A. This agent should only be given via the intramuscular route since intravenous administration has been associated with cardiopulmonary arrest and death.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bicillin L-A must be distinguished from Bicillin C-R (which contains equal concentrations of intermediate-acting procaine and long-acting
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         ) and should
         <strong>
          not
         </strong>
         be used to treat patients with syphilis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1984504721">
         <span class="h3">
          Treatment of primary, secondary, or early latent disease and post-exposure prophylaxis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single dose of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         2.4 million units intramuscularly is appropriate for patients with primary, secondary, or early latent disease and for post-exposure prophylaxis after sexual contact with a partner with known or suspected syphilis  (
         <a class="graphic graphic_table graphicRef79645" href="/z/d/graphic/79645.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Staging'
         </a>
         above).
        </p>
        <p>
        </p>
        <p>
         Some clinicians administer an additional dose of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         2.4 million units one week after the first dose to patients with primary, secondary, or early latent disease [
         <a href="#rid7">
          7
         </a>
         ], based in part on evidence of efficacy [
         <a href="#rid38">
          38-40
         </a>
         ] and on pharmacokinetic data of altered penicillin levels in pregnant people [
         <a href="#rid41">
          41,42
         </a>
         ]. There is no harm to giving a second dose, but it has not been recommended in guidelines from national organizations because the value of a second dose has not been evaluated in a randomized trial and there have been shortages of penicillin G benzathine in some countries. A second dose of penicillin is not administered to nonpregnant patients with primary, secondary, or early latent disease. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Treatment of early syphilis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2251843760">
         <span class="h3">
          Treatment of late latent and tertiary disease
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Three doses of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         2.4 million units intramuscularly at weekly intervals are recommended for late latent and tertiary syphilis  (
         <a class="graphic graphic_table graphicRef79645" href="/z/d/graphic/79645.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Pregnant people whose scheduled dose is delayed by &gt;9 days should repeat the full course of therapy [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Treatment of late syphilis'
         </a>
         .)
        </p>
        <p>
         If an asymptomatic patient with suspected latent syphilis was previously treated for syphilis but receipt of an appropriate treatment regimen cannot be verified, then the full three-dose penicillin regimen recommended for late latent syphilis should be administered. Diagnosis of treatment failure is discussed below. (See
         <a class="local">
          'Interpretation of response to therapy and diagnosis of treatment failure'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1941262489">
         <span class="h3">
          Treatment of neurosyphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of neurosyphilis is parenteral and typically requires inpatient administration  (
         <a class="graphic graphic_table graphicRef79645" href="/z/d/graphic/79645.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Treatment of neuro/ocular/otic syphilis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2214075712">
         <span class="h2">
          Patients with immediate type allergic reactions to penicillin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant people with syphilis and a history of an immediate type allergic reaction to penicillin, the
         <strong>
          only
         </strong>
         satisfactory treatment is desensitization followed by penicillin therapy [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Penicillin allergy is reported by 5 to 10 percent of pregnant people [
         <a href="#rid43">
          43
         </a>
         ]; however, serious allergic reactions to penicillin are rare. It is important to verify the history of "allergy," since the patient may incorrectly assume a nonallergic side effect (eg, nausea or vomiting) to be allergic in origin. The major symptoms of concern are immunoglobulin E (IgE)-mediated (immediate) responses, such as urticaria, angioedema or anaphylaxis with airway obstruction, bronchospasm or hypotension  (
         <a class="graphic graphic_table graphicRef71375" href="/z/d/graphic/71375.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3259546530">
         <span class="h3">
          Referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who report symptoms suggestive of a past immediate allergy to a penicillin should be evaluated with penicillin skin testing, if possible. In most cases, this involves referral to an allergist, as skin testing requires some expertise to perform and interpret. In addition, allergists can perform rapid drug desensitization protocols if appropriate. (See
         <a class="local">
          'Desensitization'
         </a>
         below.)
        </p>
        <p>
         Many patients may give a vague history of a mild reaction, such as rash, which is difficult to classify with any precision. We suggest consulting an allergist in such cases, but if an allergist is not available and the clinician believes the risk of a significant reaction is minimal, a test dose or graded challenge may be performed. Test dosing is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Graded challenge and drug provocation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2828934210">
         <span class="h3">
          Skin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Penicillin skin testing takes approximately one hour to perform and can determine if the patient has an immediate penicillin allergy.
        </p>
        <p>
         Individuals who had a true IgE-mediated reaction to penicillin in the distant past with no reexposure may lose their sensitivity over time. Approximately 80 percent of patients with a history of IgE-mediated penicillin allergy that occurred ≥10 years in the past will now have a negative skin test and can safely take penicillin. (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions", section on 'Penicillin skin testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions", section on 'Time elapsed since the reaction'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive test
         </strong>
         – Pregnant people with a positive skin test are at significant risk of a reaction to penicillin; two-thirds develop some allergic symptoms and a subset of those will have a life-threatening anaphylactic reaction [
         <a href="#rid43">
          43
         </a>
         ]. Penicillin desensitization is recommended for pregnant people with a positive skin test who require penicillin therapy. (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions", section on 'Desensitization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative test
         </strong>
         – Pregnant people with negative skin test results are at no greater risk for a reaction to penicillin than the general population and can receive the drug. However, the first dose should be given under medical supervision because the negative predictive value of skin testing, while high, is not 100 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2268642049">
         <span class="h3">
          Desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         <strong>
          It is
         </strong>
         <strong>
          strongly recommended that desensitizations be performed by allergy specialists.
         </strong>
        </p>
        <p>
         Penicillin desensitization involves exposing the patient to a small amount of penicillin and gradually increasing the dose until an effective level is reached, followed by the appropriate therapeutic penicillin regimen. Penicillin desensitization can be achieved either orally or intravenously. Oral desensitization is simpler and safer. The procedure requires approximately four hours to accomplish and requires close patient monitoring. Most adverse reactions can be managed without discontinuation of the desensitization protocol.
        </p>
        <p>
         Desensitizations are usually performed in the hospital and often in the intensive care setting because it is critical to have the staffing and equipment available to manage anaphylaxis. However, oral desensitization to penicillin has been performed by allergy specialists in the outpatient setting, with one-on-one nursing and intravenous access.
        </p>
        <p>
         Protocols for intravenous desensitizations are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions", section on 'Desensitization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H262042555">
         <span class="h2">
          Role of nonpenicillin regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         During pregnancy, nonpenicillin antibiotic regimens used for syphilis treatment in males and nonpregnant females are either contraindicated (eg,
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         ), lack sufficient data regarding efficacy (eg,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ), or do not cross the placental barrier completely so the fetus is not effectively treated (eg,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ). Therefore, they are not recommended for pregnant people.
         <strong>
          Nonpenicillin regimens should only be considered when penicillin cannot be obtained or for penicillin-allergic patients when penicillin desensitization is not possible.
         </strong>
         (See
         <a class="local">
          'Patients with immediate type allergic reactions to penicillin'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          World Health Organization (WHO) regimens
         </strong>
         –
         <strong>
         </strong>
         In parts of the world where penicillin desensitization is not possible [
         <a href="#rid44">
          44
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For nonpenicillin treatment of early syphilis (ie, primary, secondary, or latent &lt;2 years [WHO definition]) in pregnancy, administer one of the following alternative regimens:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          Erythromycin
         </a>
         500 mg orally four times daily for 14 days, or
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          Ceftriaxone
         </a>
         1 g intramuscularly once daily for 10 to 14 days, or
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         2 g once orally (when local susceptibility to azithromycin is likely)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For nonpenicillin treatment of late syphilis, administer
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         500 mg orally four times daily for 30 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infants born to individuals who were treated during pregnancy with nonpenicillin regimens should receive penicillin treatment because
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         do not cross the placental barrier completely so the fetus is not effectively treated.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Aqueous benzyl penicillin 100,000 to 150,000 U/kg/day intravenously for 10 to 15 days
        </p>
        <p>
        </p>
        <p>
         A small study in China evaluated the use of
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         for treatment of early syphilis in 11 pregnant people with a history of penicillin allergy [
         <a href="#rid45">
          45
         </a>
         ]. Preliminary results were encouraging, RPR titers fell and there were no clinical manifestations of congenital syphilis in the infants. A large scale trial of this treatment strategy is planned as an alternative to desensitization. Until the results of such trials are available, penicillin desensitization followed by penicillin treatment should be regarded as "standard of care" for the management of penicillin-allergic pregnant people with syphilis.
        </p>
        <p class="headingAnchor" id="H2644832185">
         <span class="h1">
          POTENTIAL COMPLICATIONS OF TREATMENT: JARISCH-HERXHEIMER REACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of syphilis may precipitate the Jarisch-Herxheimer reaction. The risk of occurrence of Jarisch-Herxheimer reaction is not a contraindication to syphilis treatment. However, all patients should be counseled about the risks and clinical features of this febrile reaction, and told to contact their provider if symptoms occur.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Signs and symptoms
         </strong>
         – Clinical manifestations include an acute febrile reaction accompanied by headache, myalgia, rash, and hypotension [
         <a href="#rid46">
          46
         </a>
         ]. The reaction begins within one to two hours of treatment, peaks at eight hours, and typically resolves within 24 to 48 hours. In one series, 15 out of 33 pregnant people treated for syphilis on a high risk pregnancy unit at Parkland Hospital had a Jarisch-Herxheimer reaction, including 3 out of 3 with primary syphilis, 12 out of 20 with secondary syphilis, and 0 out of 10 with latent syphilis [
         <a href="#rid46">
          46
         </a>
         ]. The reaction may be more common in people with HIV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management is supportive care (eg, antipyretics, intravenous fluids).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The clinical findings are thought to result from the release of large amounts of treponemal lipopolysaccharide from dying spirochetes and an increase in circulating cytokine levels (tumor necrosis factor alpha [TNF-alpha], interleukin-6, interleukin-8).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – The Jarisch-Herxheimer reaction may precipitate uterine contractions, preterm labor, and/or nonreassuring fetal heart rate tracings in pregnant people treated in the second half of pregnancy [
         <a href="#rid46">
          46,47
         </a>
         ]. Patients should report symptoms of labor or decreased fetal activity to their provider immediately; evaluation and treatment are according to usual obstetric standards.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of premedication
         </strong>
         – The authors do
         <strong>
          not
         </strong>
         premedicate patients. Premedication with corticosteroids [
         <a href="#rid48">
          48
         </a>
         ] or TNF-alpha antibodies [
         <a href="#rid49">
          49,50
         </a>
         ] appears to prevent the reaction, but is not widely used given limited data of the relative risks and benefits of this approach, with no data in pregnant people. In a study of 22 nonpregnant patients with primary syphilis treated with penicillin for three days, 15 patients were given penicillin alone while the other 7 received 20, 40, or 60 mg of oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         on the first and second day of antibiotic administration [
         <a href="#rid48">
          48
         </a>
         ]. Jarisch-Herxheimer reactions (defined as temperature ≥38°C) occurred more frequently in the control group (93 versus 12 percent) and in no patient who received 60 mg of prednisolone. Nonfebrile manifestations of the reaction were not evaluated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Premedication with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         or meptazinol may reduce the severity or duration of symptoms, but the reaction itself is not prevented [
         <a href="#rid51">
          51
         </a>
         ]; premedication with
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         has not been effective [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3294466460">
         <span class="h1">
          POST-TREATMENT MATERNAL FOLLOW-UP
         </span>
        </p>
        <p class="headingAnchor" id="H431708304">
         <span class="h2">
          Clinical follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with early syphilis should be assessed clinically for resolution of symptoms (eg, rash, ulcer). However, for patients with late stage cardiovascular or noncutaneous gummatous disease, a significant change in symptoms is unlikely. Monitoring is described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Clinical assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3898138373">
         <span class="h2">
          Frequency of nontreponemal titers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant people treated for early syphilis should have a nontreponemal titer checked at the time of treatment to establish a baseline against which to monitor response to treatment, since this titer may differ from that of the initial diagnostic test due to elapsed time between diagnosis and initiation of therapy. The subsequent frequency of monitoring is the same as in nonpregnant patients and depends upon the stage of disease and presence of HIV coinfection.
        </p>
        <p>
         When monitoring nontreponemal titers, the same test should be performed each time (ie, serial rapid plasma antigen or serial Venereal Disease Research Laboratory) and ideally at the same laboratory. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'How often to monitor'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H624046807">
         <span class="h3">
          Interpretation of response to therapy and diagnosis of treatment failure
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A fourfold increase in the nontreponemal titer after treatment is evidence of treatment failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A fourfold decline in the titer, equivalent to a change of two dilutions (eg, from 1:16 to 1:4 or from 1:32 to 1:8), is considered to be an acceptable response to syphilis therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A decline in maternal nontreponemal serologic titers following treatment does not guarantee that fetal treatment has been adequate. Thus, neonates should be evaluated for congenital syphilis after delivery. (See
         <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">
          "Congenital syphilis: Management and outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         There is wide patient-to-patient variability in the rate of decline in nontreponemal titers, which can be influenced by factors such as previous episodes of syphilis, HIV infection, stage of syphilis, and the level of the titer at the time of diagnosis. If the diagnostic titer is low (eg, 1:4), it is common for the rate of decline to be slower than if the diagnostic titer is high (eg, 1:128). In nonpregnant patients, an adequate response to therapy is expected by 12 months for patients with early syphilis and 24 months for patients with late syphilis, but the authors are willing to avoid retreatment as long as the titer is declining, even if the pace is slower than expected. However, in pregnancy, it is probably prudent to err on the side of overtreatment for early or late syphilis, so retreatment is reasonable if a fourfold decline from pretreatment titer has not occurred by six months.
        </p>
        <p class="headingAnchor" id="H2316906331">
         <span class="h3">
          Seroreversion and serofast states
         </span>
         <span class="headingEndMark">
          —
         </span>
         The loss of antibodies over time (seroreversion) in a patient who has been treated for syphilis is considered consistent with clinical cure. The majority of patients who are treated for syphilis will experience seroreversion over time. Issues regarding the serofast state are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Serologic testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Persons with an inadequate response to treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3005456065">
         <span class="h1">
          POTENTIAL ADVERSE PREGNANCY OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancies complicated by syphilis are at increased risk of several adverse outcomes from placental and fetal infection [
         <a href="#rid37">
          37,53-58
         </a>
         ]. Maternal treatment reduces the risk of adverse outcomes, but preterm labor can be precipitated by the Jarisch-Herxheimer reaction (see
         <a class="local">
          'Potential complications of treatment: Jarisch-Herxheimer reaction'
         </a>
         above). Adverse outcomes include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy loss
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preterm birth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stillbirth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired fetal growth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital infection  (
         <a class="graphic graphic_table graphicRef67809" href="/z/d/graphic/67809.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neonatal mortality
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          VERTICAL TRANSMISSION (CONGENITAL SYPHILIS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inadequate maternal screening and/or inadequate maternal treatment can result in congenital syphilis. Screening failures occur primarily among pregnant people who do not receive prenatal care or have late entry into prenatal care and in high-risk patients who are not rescreened in the third trimester and at delivery [
         <a href="#rid20">
          20,59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H112801766">
         <span class="h2">
          Pathogenesis of congenital infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          T. pallidum
         </em>
         readily infects the placenta. Transplacental transmission to the fetus can occur from approximately the 9
         <sup>
          th
         </sup>
         to 10
         <sup>
          th
         </sup>
         week of gestation [
         <a href="#rid60">
          60
         </a>
         ] and at any stage of maternal disease. Importantly, the manifestations of congenital infection are influenced by the gestational age, state of maternal syphilis, maternal treatment, and immunological response of the fetus.
        </p>
        <p>
         Fetal abnormalities result from a robust inflammatory response to
         <em>
          T. pallidum
         </em>
         ; thus, they are most pronounced after 20 weeks of gestation since the fetal immunologic response is poorly developed in the first half of pregnancy [
         <a href="#rid7">
          7
         </a>
         ]. After the placenta is infected, transplacental passage of spirochetes to the fetal circulation leads to fetal hepatic infection and dysfunction, followed by amniotic fluid infection, fetal hematologic abnormalities (anemia, thrombocytopenia), ascites, hydrops, and fetal immunoglobulin M (IgM) production [
         <a href="#rid61">
          61
         </a>
         ]. Hepatomegaly is thought to be caused by inflammation, extramedullary hematopoiesis, and hepatic congestion [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Neonates can also become infected during birth from contact with maternal secretions or blood containing spirochetes.
        </p>
        <p class="headingAnchor" id="H2830930174">
         <span class="h2">
          Factors influencing frequency of vertical transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         In two systematic reviews, 15 and 36 percent of infants of mothers with untreated syphilis had clinical evidence of congenital syphilis [
         <a href="#rid62">
          62,63
         </a>
         ]. Factors that increase the risk of congenital infection include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early stage syphilis
         </strong>
         – The risk of congenital infection is extremely high in the first four years after maternal acquisition of infection, when spirochetemia is common in the absence of treatment [
         <a href="#rid64">
          64-66
         </a>
         ]. When looked at by stage, the risk of congenital infection in term infants has been reported to be 50 percent for primary and secondary untreated syphilis, 40 percent for early latent untreated syphilis, and 10 percent for late untreated syphilis [
         <a href="#rid67">
          67
         </a>
         ]. When looked at by baseline titer, the risk of congenital syphilis in offspring of patients with nontreponemal titer ≥8 versus &lt;8 was 26 and 4 percent, respectively, in one systematic review [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal acquisition of infection later rather than earlier in gestation
         </strong>
         – The frequency of vertical transmission increases with increasing gestational age at acquisition of maternal infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Failure to appropriately identify and treat maternal infection
         </strong>
         – Reviews of congenital syphilis cases generally reveal that most could have been prevented [
         <a href="#rid2">
          2,68
         </a>
         ]. The majority of cases occurred because of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lack of maternal screening (often because of lack of prenatal care, sometimes because high-risk patients may not be identified if providers are uncomfortable asking questions about sexual behavior)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lack of third-trimester rescreening in high-risk patients
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lack of screening at delivery in high-risk patients and pregnant people who did not receive prenatal care
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lack of appropriate follow-up and adequate treatment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Globally, many undetected maternal cases are also due to lack of adequate antenatal care services. Although 88 percent of pregnant people globally had at least one prenatal care visit, among syphilis-infected mothers, only 51 percent of those who had a prenatal visit were adequately treated [
         <a href="#rid4">
          4
         </a>
         ]. Pregnant people who received some prenatal care but were not diagnosed or diagnosed but not treated accounted for 74 percent of the global congenital syphilis burden. Point-of-care testing and same-day treatment could be effective in antenatal care settings where loss to follow-up for test results and treatment is common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the United States, data from 2022 gathered by the CDC showed that 88 percent of mothers of congenitally infected offspring received either no or untimely syphilis testing (37 percent), no or undocumented treatment (11 percent), or inadequate treatment (40 percent) during pregnancy [
         <a href="#rid2">
          2
         </a>
         ]. Among pregnancies with a congenital syphilis outcome, no prenatal care at all was documented in 38 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to improving access to care for pregnant persons, expanded syphilis testing strategies may improve the frequency of diagnosis of maternal syphilis. Increased emphasis on testing for syphilis outside of traditional prenatal care settings (emergency departments, needle exchange programs, jail intake) and the use of point-of-care rapid tests combined with enhanced linkage to treatment and maternal care could decrease cases of congenital syphilis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1537935544">
         <span class="h2">
          Prenatal (fetal) diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal infection should be suspected if there are characteristic findings on ultrasound examination after 20 weeks of gestation in a pregnant person with untreated or inadequately treated syphilis. Before 18 to 20 weeks, fetal abnormalities are not usually seen because of fetal immunologic immaturity. (See
         <a class="local">
          'Pathogenesis of congenital infection'
         </a>
         above.)
        </p>
        <p>
         Findings on ultrasound are nonspecific and included the following in one review [
         <a href="#rid69">
          69
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatomegaly, defined as liver length &gt;95
         <sup>
          th
         </sup>
         percentile for gestational age (83 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anemia, based on Doppler middle cerebral artery peak systolic velocity &gt;1.5 multiples of the median (38 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placentomegaly, defined as placental thickness &gt;2 standard deviations above mean for gestational age (34 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Growth restriction (14 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydrops (12 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin edema 7 percent, pericardial effusion 2 percent, ascites 19 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyhydramnios (11 percent), oligohydramnios (9 percent)
        </p>
        <p>
        </p>
        <p>
         Hepatomegaly and placentomegaly are early findings. Anemia, ascites, and hydrops occur later in the course of infection.
        </p>
        <p>
         An abnormal ultrasound is not diagnostic of fetal infection and a normal ultrasound does not exclude fetal infection. In one series, congenital syphilis was diagnosed in 39 percent of infants of seropositive mothers who had a pretreatment fetal ultrasound with one or more of the above findings and in 12 percent of infants when the ultrasound examination was normal [
         <a href="#rid70">
          70
         </a>
         ]. Some manifestations of congenital disease are subtle and/or not seen on prenatal ultrasound examination (eg, ocular and osseous abnormalities). (See
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Early congenital syphilis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">
          "Congenital syphilis: Management and outcome"
         </a>
         .)
        </p>
        <p>
         Diagnostic testing of amniotic fluid or fetal blood definitively establishes intrauterine infection, but invasive procedures to obtain these specimens can be associated with complications, do not change management, and thus are not recommended. Potential fetal laboratory manifestations of infection were illustrated in a series of 24 pregnant people with primary, secondary, or early latent syphilis diagnosed after 24 weeks of gestation who underwent funipuncture [
         <a href="#rid61">
          61
         </a>
         ]. The following abnormalities were noted: abnormal liver chemistries (88 percent), thrombocytopenia (35 percent), anemia (26 percent), and positive fetal antitreponemal IgM (13 percent).
        </p>
        <p class="headingAnchor" id="H3464215100">
         <span class="h2">
          Fetal treatment and treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal penicillin treatment is curative for fetal infection in most cases. Although fetal anemia is one of the adverse sequelae of congenital infection, intrauterine transfusion is rarely necessary as appropriate treatment of maternal infection generally reverses the anemia [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Congenital infection has been diagnosed in 1 to 2 percent of offspring of mothers adequately treated during pregnancy compared with 70 to 100 percent of offspring of untreated mothers. The WHO estimates that treatment reduces early fetal deaths or stillbirths by 82 percent, preterm or low birth weight by 65 percent, neonatal deaths by 80 percent, and clinical disease in infants by 97 percent [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         In an observational series of 43 treatment failures, the following characteristics were more likely in adequately treated patients who went on to have congenitally infected infants [
         <a href="#rid66">
          66
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High nontreponemal titer at treatment and delivery
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Birth ≤36 weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early stage infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short interval (≤30 days) between treatment and giving birth
        </p>
        <p>
        </p>
        <p>
         The authors hypothesized that high treponemal load, altered penicillin pharmacokinetics in pregnancy, and inadequate time for fetal therapeutic response may have accounted for the treatment failures.
        </p>
        <p class="headingAnchor" id="H3239120125">
         <span class="h2">
          Newborn evaluation and treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations, diagnosis, treatment, and prognosis of congenital syphilis in the neonate are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">
          "Congenital syphilis: Management and outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H530082643">
         <span class="h1">
          PREGNANCY MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancies in people with syphilis should be comanaged by obstetric and infectious disease specialists.
        </p>
        <p class="headingAnchor" id="H2738116912">
         <span class="h2">
          Ultrasound examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         At least one ultrasound examination after 20 weeks of gestation should be performed to look for signs of congenital infection. In pregnancies with a presumptive sonographic diagnosis of congenital syphilis, ultrasound examinations should be performed every one or two weeks to assess fetal well-being and the fetal response to treatment.
        </p>
        <p>
         With successful fetal treatment, middle cerebral arterial Doppler abnormalities, ascites, and polyhydramnios resolve first (usually within approximately one month), followed by placentomegaly, and lastly hepatomegaly. Hepatomegaly can take months to resolve after maternal treatment [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3553711845">
         <span class="h2">
          Delivery issues
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late preterm delivery for neonatal treatment is indicated when there is a high risk of fetal treatment failure (eg, progressive worsening signs of congenital syphilis on ultrasound examination, hydrops) [
         <a href="#rid7">
          7,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient first presents for pregnancy care when they are in labor and their nontreponemal or treponemal test is positive, maternal evaluation and treatment for syphilis are performed as described above; intrapartum care and procedures are not impacted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At delivery, pediatric providers should be notified about maternal syphilis stage and treatment, and fetal ultrasound findings. (See
         <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">
          "Congenital syphilis: Management and outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H147332523">
         <span class="h2">
          Placenta
         </span>
         <span class="headingEndMark">
          —
         </span>
         The placenta/fetal membranes should be sent for histopathologic examination. The pathologist should be notified about maternal syphilis stage and treatment.
        </p>
        <p>
         The placenta in people with untreated syphilis is typically large and edematous. Characteristic placental findings include  (
         <a class="graphic graphic_picture graphicRef59074" href="/z/d/graphic/59074.html" rel="external">
          picture 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydrops placentalis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic villitis (plasma cells, mixed acute and chronic infiltrate)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perivillous fibrous proliferation (onion skin vessels)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normoblastemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Necrotizing funisitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute chorioamnionitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma cell deciduitis
        </p>
        <p>
        </p>
        <p>
         These pathological changes can adversely affect fetoplacental exchange of oxygen and nutrients, which may account, at least in part, for some adverse fetal outcomes [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Silver stain should reveal the spirochetes, but they are often very difficult to identify. The best yield is often in the decidua basalis or capsularis where there are plasma cells or, in cases of fetal death, in the vitreous.
        </p>
        <p class="headingAnchor" id="H110251012">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">
          "Society guideline links: Sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H180673701">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83398.html" rel="external">
          "Patient education: Congenital syphilis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical findings
         </strong>
         – Each stage of syphilis has characteristic maternal clinical features that are not altered by pregnancy  (
         <a class="graphic graphic_table graphicRef79946" href="/z/d/graphic/79946.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Staging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Diagnostic evaluation for maternal syphilis is the same in pregnant and nonpregnant individuals. A maternal diagnosis of syphilis is made when both nontreponemal and treponemal tests are reactive. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening
         </strong>
         – We recommend screening all pregnant people for syphilis (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Maternal screening'
         </a>
         above.).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All pregnant people: screen at the first prenatal encounter
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pregnant people at high risk of infection: repeat screening at 28 to 32 weeks and at delivery
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pregnant people who have not been screened in pregnancy or who deliver a stillborn after 20 weeks of gestation: screen at delivery
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          False-positive screening tests
         </strong>
         – False-positive screening tests may be more common in the setting of pregnancy. Confirmatory testing must be performed  (
         <a class="graphic graphic_algorithm graphicRef116084" href="/z/d/graphic/116084.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'False-positive serologic tests in pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         –
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          Penicillin G benzathine
         </a>
         is the standard for the treatment of syphilis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          Penicillin G benzathine
         </a>
         therapy is effective for treating maternal disease, preventing transmission to the fetus, and treating established fetal disease. The long-acting intramuscular formulation must be used (Bicillin L-A); Bicillin C-R (which contains equal concentrations of intermediate-acting procaine and long-acting benzathine penicillin) should
         <strong>
          not
         </strong>
         be used to treat patients with syphilis. (See
         <a class="local">
          'Maternal treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The appropriate
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         regimen depends on the stage of disease  (
         <a class="graphic graphic_table graphicRef79645" href="/z/d/graphic/79645.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Primary, secondary, or early latent disease
         </strong>
         : a single dose of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         2.4 million units intramuscularly. Some clinicians administer an additional dose of penicillin G benzathine 2.4 million units one week after the first dose. (See
         <a class="local">
          'Treatment of primary, secondary, or early latent disease and post-exposure prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Late latent, tertiary, and disease of unknown duration
         </strong>
         : three doses of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         2.4 million unit intramuscularly at weekly intervals. If a dose is missed for more than 14 days, the full three dose course of therapy should be started again. (See
         <a class="local">
          'Treatment of late latent and tertiary disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If an asymptomatic patient with what could be latent syphilis was previously treated for syphilis but receipt of an appropriate treatment regimen cannot be verified, the full three-dose penicillin regimen recommended for late latent syphilis should be administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Desensitization in penicillin allergy
         </strong>
         – We recommend desensitization for penicillin-allergic pregnant patients followed by
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Alternative drugs are not as safe for the pregnant person or fetus or not as effective for prevention of congenital syphilis. (See
         <a class="local">
          'Patients with immediate type allergic reactions to penicillin'
         </a>
         above and
         <a class="local">
          'Role of nonpenicillin regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Jarisch-Herxheimer reaction
         </strong>
         – Treatment of syphilis may precipitate the Jarisch-Herxheimer reaction, which may precipitate uterine contractions, preterm labor, and/or nonreassuring fetal heart rate tracing in pregnant people treated in the second half of pregnancy. Maternal discomfort is treated with supportive care and pregnancy complications are managed by standard obstetric protocols. (See
         <a class="local">
          'Potential complications of treatment: Jarisch-Herxheimer reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal follow-up
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pregnant people treated for early syphilis should have a titer checked just before treatment, since it is not uncommon for this titer to be higher than that of the initial diagnostic titer due to elapsed time between diagnosis and therapy. The subsequent frequency of monitoring is the same as in nonpregnant patients and depends upon the stage of disease and presence of HIV coinfection. When monitoring nontreponemal titers, the same test, preferably the rapid plasmin regain (RPR), should be performed each time and at the same laboratory. (See
         <a class="local">
          'Frequency of nontreponemal titers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A fourfold increase in the nontreponemal titer after treatment is always abnormal. A fourfold decline in the titer, equivalent to a change of two dilutions (eg, from 1:16 to 1:4 or from 1:32 to 1:8), is considered to be an acceptable response to syphilis therapy; however, this can take months to achieve. A fall in maternal titers does not guarantee that fetal treatment has been adequate. (See
         <a class="local">
          'Interpretation of response to therapy and diagnosis of treatment failure'
         </a>
         above and
         <a class="local">
          'Ultrasound examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vertical transmission
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Frequency
         </strong>
         – The frequency of vertical transmission is higher with early stage than late stage syphilis. Among people who acquire syphilis during pregnancy, the risk of vertical transmission increases with increasing gestational age at acquisition of maternal infection. (See
         <a class="local">
          'Vertical transmission (congenital syphilis)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prenatal diagnosis
         </strong>
         – Fetal infection should be suspected if there are characteristic findings on ultrasound examination after 20 weeks of gestation in a patient with untreated or inadequately treated syphilis. Hepatomegaly and placentomegaly are early sonographic findings suggestive of congenital syphilis. Anemia, ascites, and hydrops occur later in the course of fetal infection. An abnormal ultrasound is not diagnostic of fetal infection and a normal ultrasound does not exclude fetal infection. (See
         <a class="local">
          'Prenatal (fetal) diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment
         </strong>
         – Maternal
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         treatment is curative for fetal infection in most cases. Maternal treatment ≤30 days before delivery is a risk factor for congenital infection. (See
         <a class="local">
          'Fetal treatment and treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          National Overview of STDs. Centers of Disease Control and Prevention. Available at: https://www.cdc.gov/std/statistics/2021/overview.htm#Syphilis (Accessed on November 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald R, O'Callaghan K, Torrone E, et al. Vital Signs: Missed Opportunities for Preventing Congenital Syphilis - United States, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:1269.
          </a>
         </li>
         <li class="breakAll">
          Sexually Transmitted Disease Surveillance 2021. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/std/statistics/2021/default.htm (Accessed on November 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korenromp EL, Rowley J, Alonso M, et al. Global burden of maternal and congenital syphilis and associated adverse birth outcomes-Estimates for 2016 and progress since 2012. PLoS One 2019; 14:e0211720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman L, Rowley J, Vander Hoorn S, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One 2015; 10:e0143304.
          </a>
         </li>
         <li class="breakAll">
          United States Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2019. https://www.cdc.gov/std/statistics/2019/default.htm (Accessed on August 02, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rac MW, Revell PA, Eppes CS. Syphilis during pregnancy: a preventable threat to maternal-fetal health. Am J Obstet Gynecol 2017; 216:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi S, Williams C, Torrone E, Kidd S. National Trends and Reported Risk Factors Among Pregnant Women With Syphilis in the United States, 2012-2016. Obstet Gynecol 2019; 133:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ROCKWELL DH, YOBS AR, MOORE MB Jr. THE TUSKEGEE STUDY OF UNTREATED SYPHILIS; THE 30TH YEAR OF OBSERVATION. Arch Intern Med 1964; 114:792.
          </a>
         </li>
         <li class="breakAll">
          Sparling PF. Natural history of syphilis. In: Sexually Transmitted Diseases, Holmes KK, Mardh PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.213.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman L, Kamb M, Hawkes S, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med 2013; 10:e1001396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng JQ, Zhou H, Hong FC, et al. Syphilis screening and intervention in 500,000 pregnant women in Shenzhen, the People's Republic of China. Sex Transm Infect 2007; 83:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qin JB, Feng TJ, Yang TB, et al. Synthesized prevention and control of one decade for mother-to-child transmission of syphilis and determinants associated with congenital syphilis and adverse pregnancy outcomes in Shenzhen, South China. Eur J Clin Microbiol Infect Dis 2014; 33:2183.
          </a>
         </li>
         <li class="breakAll">
          Royal College of Obstetricians and Gynaecologists. National evidence-based clinical guidelines. Antenatal care: Routine care for the healthy pregnant woman. www.rcog.org.uk/index.asp?PageID=693 (Accessed on March 28, 2006).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hossain M, Broutet N, Hawkes S. The elimination of congenital syphilis: a comparison of the proposed World Health Organization action plan for the elimination of congenital syphilis with existing national maternal and congenital syphilis policies. Sex Transm Dis 2007; 34:S22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolff T, Shelton E, Sessions C, Miller T. Screening for syphilis infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009; 150:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics Committee on Fetus and Newborn and Amercian College of Obstetricians and Gynecologists Committee on Obstetric Practice. Guidelines for Perinatal Care, 8th, Kilpatrick SJ, Papile L (Eds), 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Syphilis Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2018; 320:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geusau A, Kittler H, Hein U, et al. Biological false-positive tests comprise a high proportion of Venereal Disease Research Laboratory reactions in an analysis of 300,000 sera. Int J STD AIDS 2005; 16:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinajeros F, Grossman D, Richmond K, et al. Diagnostic accuracy of a point-of-care syphilis test when used among pregnant women in Bolivia. Sex Transm Infect 2006; 82 Suppl 5:v17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albright CM, Emerson JB, Werner EF, Hughes BL. Third-Trimester Prenatal Syphilis Screening: A Cost-Effectiveness Analysis. Obstet Gynecol 2015; 126:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hersh AR, Megli CJ, Caughey AB. Repeat Screening for Syphilis in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis. Obstet Gynecol 2018; 132:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huntington S, Weston G, Seedat F, et al. Repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK: a cost-effectiveness analysis. BMJ Open 2020; 10:e038505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogozińska E, Kara-Newton L, Zamora JR, Khan KS. On-site test to detect syphilis in pregnancy: a systematic review of test accuracy studies. BJOG 2017; 124:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandenburger D, Ambrosino E. The impact of antenatal syphilis point of care testing on pregnancy outcomes: A systematic review. PLoS One 2021; 16:e0247649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee Opinion No. 752: Prenatal and Perinatal Human Immunodeficiency Virus Testing. Obstet Gynecol 2018; 132:e138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor NP, Burke PC, Worley S, et al. Outcomes After Positive Syphilis Screening. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JS, Eder ML, Bean SI. Screening for Syphilis Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320:918.
          </a>
         </li>
         <li class="breakAll">
          Possible False RPR Reactivity with BioPlex 2200 Syphilis Total &amp; RPR Test Kit Following a COVID-19 Vaccine - Letter to Clinical Laboratory Staff and Health Care Providers. US Food and Drug Administration. Available at: https://www.fda.gov/medical-devices/letters-health-care-providers/possible-false-rpr-reactivity-bioplex-2200-syphilis-total-rpr-test-kit-following-covid-19-vaccine (Accessed on June 29, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang KD, Xu DJ, Su JR. Preferable procedure for the screening of syphilis in clinical laboratories in China. Infect Dis (Lond) 2016; 48:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henrich TJ, Yawetz S. Impact of age, gender, and pregnancy on syphilis screening using the Captia Syphilis-G assay. Sex Transm Dis 2011; 38:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boonchaoy A, Wongchampa P, Hirankarn N, Chaithongwongwatthana S. Performance of Chemiluminescent Microparticle Immunoassay in Screening for Syphilis in Pregnant Women from Low-Prevalence, Resource-Limited Setting. J Med Assoc Thai 2016; 99:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mmeje O, Chow JM, Davidson L, et al. Discordant Syphilis Immunoassays in Pregnancy: Perinatal Outcomes and Implications for Clinical Management. Clin Infect Dis 2015; 61:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellinghausen N, Dietenberger H. Evaluation of two automated chemiluminescence immunoassays, the LIAISON Treponema Screen and the ARCHITECT Syphilis TP, and the Treponema pallidum particle agglutination test for laboratory diagnosis of syphilis. Clin Chem Lab Med 2011; 49:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray JG. Lues-lues: maternal and fetal considerations of syphilis. Obstet Gynecol Surv 1995; 50:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wendel GD Jr, Sheffield JS, Hollier LM, et al. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis 2002; 35:S200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu L, Qin M, Du L, et al. Maternal and congenital syphilis in Shanghai, China, 2002 to 2006. Int J Infect Dis 2010; 14 Suppl 3:e45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkes S, Matin N, Broutet N, Low N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis 2011; 11:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan L, Bawdon RE, Sidawi JE, et al. Penicillin levels following the administration of benzathine penicillin G in pregnancy. Obstet Gynecol 1993; 82:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weeks JW, Myers SR, Lasher L, et al. Persistence of penicillin G benzathine in pregnant group B streptococcus carriers. Obstet Gynecol 1997; 90:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wendel GD Jr, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312:1229.
          </a>
         </li>
         <li class="breakAll">
          WHO GUIDELINES FOR THE TREATMENT OF TREPONEMA PALLIDUM (SYPHILIS) http://apps.who.int/iris/bitstream/handle/10665/249572/9789241549806-eng.pdf;jsessionid=AF41E61DF3856FC93F39BD8D2466AC64?sequence=1 (Accessed on March 30, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou P, Gu Z, Xu J, et al. A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy. Sex Transm Dis 2005; 32:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein VR, Cox SM, Mitchell MD, Wendel GD Jr. The Jarisch-Herxheimer reaction complicating syphilotherapy in pregnancy. Obstet Gynecol 1990; 75:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myles TD, Elam G, Park-Hwang E, Nguyen T. The Jarisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis. Obstet Gynecol 1998; 92:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudjónsson H, Skog E. The effect of prednisolone on the Jarisch-Herxheimer reaction. Acta Derm Venereol 1968; 48:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coxon RE, Fekade D, Knox K, et al. The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever. QJM 1997; 90:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005; 30:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remick DG, Negussie Y, Fekade D, Griffin G. Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. J Infect Dis 1996; 174:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FIUMARA NJ, FLEMING WL, DOWNING JG, GOOD FL. The incidence of prenatal syphilis at the Boston City Hospital. N Engl J Med 1952; 247:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricci JM, Fojaco RM, O'Sullivan MJ. Congenital syphilis: the University of Miami/Jackson Memorial Medical Center experience, 1986-1988. Obstet Gynecol 1989; 74:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FIUMARA NJ. Congenital syphilis in Massachusetts. N Engl J Med 1951; 245:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giakoumelou S, Wheelhouse N, Cuschieri K, et al. The role of infection in miscarriage. Hum Reprod Update 2016; 22:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lago EG, Vaccari A, Fiori RM. Clinical features and follow-up of congenital syphilis. Sex Transm Dis 2013; 40:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulersen M, Lenchner E, Eliner Y, et al. Risk factors and adverse outcomes associated with syphilis infection during pregnancy. Am J Obstet Gynecol MFM 2023; 5:100957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mascola L, Pelosi R, Blount JH, et al. Congenital syphilis. Why is it still occurring? JAMA 1984; 252:1719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harter C, Benirschke K. Fetal syphilis in the first trimester. Am J Obstet Gynecol 1976; 124:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollier LM, Harstad TW, Sanchez PJ, et al. Fetal syphilis: clinical and laboratory characteristics. Obstet Gynecol 2001; 97:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomez GB, Kamb ML, Newman LM, et al. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. Bull World Health Organ 2013; 91:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qin J, Yang T, Xiao S, et al. Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis. PLoS One 2014; 9:e102203.
          </a>
         </li>
         <li class="breakAll">
          Harman NB. Staying the Plague, Methuen &amp; Co., LTD, London 1917.
         </li>
         <li>
          <a class="nounderline abstract_t">
           INGRAHAM NR Jr. The value of penicillin alone in the prevention and treatment of congenital syphilis. Acta Derm Venereol Suppl (Stockh) 1950; 31:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheffield JS, Sánchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am J Obstet Gynecol 2002; 186:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiumara NJ. Syphilis in newborn children. Clin Obstet Gynecol 1975; 18:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin R. Why Are Mothers Still Passing Syphilis to Their Babies? JAMA 2019; 321:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           David M, Hcini N, Mandelbrot L, et al. Fetal and neonatal abnormalities due to congenital syphilis: A literature review. Prenat Diagn 2022; 42:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rac MW, Bryant SN, McIntire DD, et al. Progression of ultrasound findings of fetal syphilis after maternal treatment. Am J Obstet Gynecol 2014; 211:426.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blencowe H, Cousens S, Kamb M, et al. Lives Saved Tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality. BMC Public Health 2011; 11 Suppl 3:S9.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4794 Version 81.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.cdc.gov/std/statistics/2021/overview.htm#Syphilis" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Overview of STDs. Centers of Disease Control and Prevention. Available at: https://www.cdc.gov/std/statistics/2021/overview.htm#Syphilis (Accessed on November 07, 2023).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37971936" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Vital Signs: Missed Opportunities for Preventing Congenital Syphilis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37971936" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Vital Signs: Missed Opportunities for Preventing Congenital Syphilis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30811406" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Global burden of maternal and congenital syphilis and associated adverse birth outcomes-Estimates for 2016 and progress since 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646541" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646541" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27956203" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Syphilis during pregnancy: a preventable threat to maternal-fetal health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30531570" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : National Trends and Reported Risk Factors Among Pregnant Women With Syphilis in the United States, 2012-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14211593" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : THE TUSKEGEE STUDY OF UNTREATED SYPHILIS; THE 30TH YEAR OF OBSERVATION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14211593" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : THE TUSKEGEE STUDY OF UNTREATED SYPHILIS; THE 30TH YEAR OF OBSERVATION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23468598" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17693449" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Syphilis screening and intervention in 500,000 pregnant women in Shenzhen, the People's Republic of China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24973132" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Synthesized prevention and control of one decade for mother-to-child transmission of syphilis and determinants associated with congenital syphilis and adverse pregnancy outcomes in Shenzhen, South China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24973132" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Synthesized prevention and control of one decade for mother-to-child transmission of syphilis and determinants associated with congenital syphilis and adverse pregnancy outcomes in Shenzhen, South China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17592387" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The elimination of congenital syphilis: a comparison of the proposed World Health Organization action plan for the elimination of congenital syphilis with existing national maternal and congenital syphilis policies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451578" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Screening for syphilis infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Sexually transmitted diseases treatment guidelines, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sexually transmitted diseases treatment guidelines, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30193283" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Screening for Syphilis Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16303064" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Biological false-positive tests comprise a high proportion of Venereal Disease Research Laboratory reactions in an analysis of 300,000 sera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17121762" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diagnostic accuracy of a point-of-care syphilis test when used among pregnant women in Bolivia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sexually Transmitted Infections Treatment Guidelines, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26244531" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Third-Trimester Prenatal Syphilis Screening: A Cost-Effectiveness Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30095767" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Repeat Screening for Syphilis in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33444184" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK: a cost-effectiveness analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28029229" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : On-site test to detect syphilis in pregnancy: a systematic review of test accuracy studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33765040" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The impact of antenatal syphilis point of care testing on pregnancy outcomes: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30134428" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : ACOG Committee Opinion No. 752: Prenatal and Perinatal Human Immunodeficiency Virus Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36000336" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Outcomes After Positive Syphilis Screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30193282" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Screening for Syphilis Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30193282" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Screening for Syphilis Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26313112" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Preferable procedure for the screening of syphilis in clinical laboratories in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22082723" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Impact of age, gender, and pregnancy on syphilis screening using the Captia Syphilis-G assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27249890" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Performance of Chemiluminescent Microparticle Immunoassay in Screening for Syphilis in Pregnant Women from Low-Prevalence, Resource-Limited Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26063719" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Discordant Syphilis Immunoassays in Pregnancy: Perinatal Outcomes and Implications for Clinical Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21619473" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Evaluation of two automated chemiluminescence immunoassays, the LIAISON Treponema Screen and the ARCHITECT Syphilis TP, and the Treponema pallidum particle agglutination test for laboratory diagnosis of syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8584292" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lues-lues: maternal and fetal considerations of syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12353207" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Treatment of syphilis in pregnancy and prevention of congenital syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20137991" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Maternal and congenital syphilis in Shanghai, China, 2002 to 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21683653" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8355931" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Penicillin levels following the administration of benzathine penicillin G in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9241301" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Persistence of penicillin G benzathine in pregnant group B streptococcus carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3921835" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Penicillin allergy and desensitization in serious infections during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3921835" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Penicillin allergy and desensitization in serious infections during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16041252" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2304710" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The Jarisch-Herxheimer reaction complicating syphilotherapy in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9794683" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The Jarisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4174097" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The effect of prednisolone on the Jarisch-Herxheimer reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8663853" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093599" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15896248" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8769625" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14941281" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The incidence of prenatal syphilis at the Boston City Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2812644" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Congenital syphilis: the University of Miami/Jackson Memorial Medical Center experience, 1986-1988.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14875223" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Congenital syphilis in Massachusetts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26386469" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The role of infection in miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23324972" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical features and follow-up of congenital syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37028553" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Risk factors and adverse outcomes associated with syphilis infection during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6471297" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Congenital syphilis. Why is it still occurring?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/56895" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Fetal syphilis in the first trimester.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11384701" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Fetal syphilis: clinical and laboratory characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23476094" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25025232" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25025232" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14829195" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The value of penicillin alone in the prevention and treatment of congenital syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904625" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Congenital syphilis after maternal treatment for syphilis during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1091383" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Syphilis in newborn children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30725108" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Why Are Mothers Still Passing Syphilis to Their Babies?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35352829" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Fetal and neonatal abnormalities due to congenital syphilis: A literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24907700" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Progression of ultrasound findings of fetal syphilis after maternal treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21501460" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Lives Saved Tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
